BRIEF — Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr — 002

Oct 12 (Reuters) — ArriVent BioPharma, Inc.: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/napi2b Dual Target Adc, Arr-002 Source text:... Further company coverage: AVBP.O (Reuters.Briefs@thomsonreuters.com;)